Clinical and comparative utility of afatinib in non-small cell lung cancer

References

• RowinskiEKThe erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitorsAnnu Rev Med20045543345714746530
   PubMed Web of Science ®Google Scholar
• KumarAPetriETHalmosBStructure and relevance of the epidermal growth factor receptor in human cancerJ Clin Oncol2008261742175118375904
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• LeeJSParkKKimS-WA randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lungJ Thor Oncol20094Suppl 19 abst PRS 4
   Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• ZhouCCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutations-positive non-small cell lung cancer (EURTAC) a multicenter, open-label, randomized phase 3 trial. Results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811
   PubMed Web of Science ®Google Scholar
• BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinoma with acquired resistance to kinase inhibitorsClin Cancer Res2006126494650117085664
   PubMed Web of Science ®Google Scholar
• EngelmanJAZajnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med2011375ra26
   PubMed Web of Science ®Google Scholar
• KosakaTYatabeYEndohHAnalysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinibClin Cancer Res2006125764576917020982
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med20052252(3)e7315737014
   PubMed Web of Science ®Google Scholar
• Godin-HeymannNBryantIRiveraMNOncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationCancer Res2006677319732617671201
   PubMed Web of Science ®Google Scholar
• InukaiMToyookaSItoSPresence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancerCancer Res200826678547858
   Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• SolcaFDahlGZoephelATarget binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blockerJ Pharmacol Exp Ther2012343234235022888144
   PubMed Web of Science ®Google Scholar
• StopferPMArzinKNarjesHAfatinib pharmacokinetics and metabolism after oral administration to healthy male volunteersCancer Chemother Pharmacol20126941051106122200729
   PubMed Web of Science ®Google Scholar
• YapTAVidalLAdamJPhase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsJ Clin Oncol201028253965397220679611
   PubMed Web of Science ®Google Scholar
• WindSSchmidMErhardtJGoeldnerRGStopferPPharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumoursClin Pharmacokinet201352121101110923813493
   PubMed Web of Science ®Google Scholar
• YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPLUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lungJ Clin Oncol201331Suppl abst 8016
   Google Scholar
• FDASummary of Safety and Effectiveness Data (SSED) http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120022b.pdfAccessed February 11, 2014
   Google Scholar
• YangJC-HSequistLVGeaterSLActivity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancerOral presentation at: World Congress on Lung CancerOctober 27–31, 2013Sydney, Australia
   Google Scholar
• WuJYYuCJChangYCEffectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancerClin Cancer Res201117113812382121531810
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimLUX-Lung 7: a phase IIb trial of afatinib (BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung Available from: http://clinicaltrials.gov/ct2/show/NCT01466660. NLM identifier: NCT01466660Accessed October 21, 2013
   Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol201028235736019949011
   PubMed Web of Science ®Google Scholar
• NanjoSYamadaTNishiharaHAbility of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitorsPLoS One2013812e8470024386407
   PubMed Web of Science ®Google Scholar
• KatakamiNAtagiSGotoKLUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib or bothJ Clin Oncol201331273335334123816963
   PubMed Web of Science ®Google Scholar
• JanjigianYYGroenHJHornLActivity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinibJ Clin Oncol201129Suppl abst 7525
   Google Scholar
• RegalesLGongYShenRDual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancerJ Clin Invest2009119103000301019759520
   PubMed Web of Science ®Google Scholar
• LacoutureMESchadendorfDChuCYDermatologic adverse events associated with afatinib: an oral ErbB family blockerExpert Rev Anticancer Ther201313672172823506519
   PubMed Web of Science ®Google Scholar
• YangJCReguartNBarinoffJDiarrhea associated with afatinib: an oral ErbB family blockerExpert Rev Anticancer Ther201313672973623506556
   PubMed Web of Science ®Google Scholar
• HirshVCadranelJCongXJSymptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1)J Thorac Oncol2013822923723328549
   PubMed Web of Science ®Google Scholar
• YangJCHirshVSchulerMSymptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273342335023816967
   PubMed Web of Science ®Google Scholar
• GeaterSLZhouCHuCLUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutationsAbstract at: World Congress on Lung CancerOctober 27–31, 2013Sydney, Australia abst 8061
   Google Scholar